top of page

Science & Applications

shutterstock_602534855 1 (1).png
shutterstock_626488493-(1)_edited_edited

ASD RESEARCH SUMMARY

Check out a summary of our research to learn how Cannabis-Responsive™ biomarkers will help physicians, families, and patients with autism take a precision medicine approach to medical cannabis treatments.

RESEARCH PAPERS

Scientific-Paper-Icon-Cannformatics-02.png
Journal of Neurology & Neuromedicine
January 2024

The Importance of Data Sources for Machine Learning Applications in Autism: A Mini Review

The mini-review extends beyond autism research, offering a glimpse into the potential of machine learning and pharmacometabolomics in a range of endocannabinoid system-related disorders. 

shutterstock_1221615613 [Converted]-01 (
Scientific-Paper-Icon-Cannformatics-02.png
Scientific Reports
August 2023

A Machine Learning Approach for Understanding the Metabolomics Response of Children with Autism Spectrum Disorder to Medical Cannabis Treatment 

The paper showcases the potential of Cannformatics Cannabis-Responsive biomarker database to define the mechanism of action (MOA) and therapeutic window for every major cannabinoid.

Scientific-Paper-Icon-Cannformatics-02.png
Cannabinoid & Cannabis Research
March 2022

The Potential of Salivary Lipid-Based Cannabis-Responsive Biomarkers to Evaluate Medical Cannabis Treatment in Children with Autism Spectrum Disorder

This paper demonstrates that Cannabis-Responsive biomarkers can provide life science companies and clinicians with new tools for understanding the role of cannabis in maintaining homeostasis of the central nervous system in children with ASD. This study also opens new opportunities to evaluate medical cannabis treatment in neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and ALS.

Scientific-Paper-Icon-Cannformatics-02.png
Cannabinoid & Cannabis Research
December 2021

Cannabis-Responsive Biomarkers: A Pharmacometabolomics-Based Application to Evaluate the Impact of Medical Cannabis Treatment on Children with Autism Spectrum Disorder

The paper establishes Cannabis-Responsive biomarkers as a universal measurement of cannabis impact. The study positions medical cannabis as the only peer-reviewed published treatment to show a shift towards the physiological range in children with autism.

LETTERS TO THE EDITOR

Journal of Anesthesia & Analgesia

Cannabis-Responsive Biomarkers: Answering the Call for Critical Appraisal of Medical Cannabis

The Letter to the Editor is in response to an editorial the journal published titled, "Cannabis as a Therapeutic or Snake Oil? A Desperate Call for Critical Appraisal of the Literature."  In our letter we outline how Cannabis-Responsive biomarkers replaces subjective evaluation with a pharmacometabolomics-based approach which show the metabolic benefits of medical cannabis treatment in children with autism spectrum disorder.

shutterstock_626488493-blue-01 (1).png
GET INVOLVED

If you are interested in getting updates from Cannformatics and are interested in specific areas of development, please sign up below.

Thanks for submitting!

If you selected "Other" above, please provide more detail below:

bottom of page